Intelligence · Clinical Development
Pipeline search results
Programs matching “aflibercept” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 79 pipeline programs matching "aflibercept" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
13406
Regeneron UK Limited
Macular Degeneration
1 trial -
14130
Regeneron UK Limited
Retinal Vein Occlusion
1 trial -
15161
Regeneron UK Limited
Macular Edema
1 trial -
15161
Bayer HealthCare AG
Macular Edema
1 trial -
2-mg Intravitreous Aflibercept Injection
Regeneron UK Limited
Proliferative Diabetic Retinopathy
1 trial -
2.0 mg intravitreal aflibercept
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
22153
Regeneron UK Limited
Macular Edema Secondary to Retinal Vein Occlusion
1 trial -
8 mg aflibercept (BAY 86-5321) (High Dose)
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Aflibercept
Regeneron UK Limited
Colorectal Cancer Metastatic
3 trials -
Aflibercept
Regeneron UK Limited
Prostatic Neoplasms
1 trial -
Aflibercept
Hoffmann-La Roche
Diabetic Macular Edema
1 trial -
Aflibercept (EYLEA, BAY86-5321)
Regeneron UK Limited
Glaucoma, Neovascular
1 trial -
Aflibercept (Eylea, BAY 86-5321)
Regeneron UK Limited
Glaucoma, Neovascular
1 trial -
Aflibercept 8 mg
Regeneron UK Limited
Neovascular Age-Related Macular Degeneration
1 trial -
Aflibercept AVE0005
Regeneron UK Limited
Colorectal Cancer Metastatic
2 trials -
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)
Regeneron UK Limited
Neovascular Age-Related Macular Degeneration
1 trial -
EFC10261
Regeneron UK Limited
Carcinoma
1 trial -
EFC10547
Regeneron UK Limited
Pancreatic Neoplasm
1 trial -
EFC6125
Regeneron UK Limited
Ovarian Neoplasms
2 trials -
Eylea (Aflibercept, BAY86-5321)
Regeneron UK Limited
Retinopathy of Prematurity (ROP)
2 trials -
Intravitreal Aflibercept Injection (IAI)
Regeneron UK Limited
Proliferative Diabetic Retinopathy
1 trial -
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Regeneron UK Limited
Branch Retinal Vein Occlusion
1 trial -
Intravitreal aflibercept injection [IAI]
Regeneron UK Limited
Nonproliferative Diabetic Retinopathy
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.